title: Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
abstract: Prostate cancer is the most prevalent male urogenital malignancy. Approximately 30% of patients with prostate cancer will develop advanced disease. Androgen deprivation therapy achieves disease control in about 90% of these patients, but the majority of them will eventually develop progressive disease, a status called castration-resistant prostate carcinoma (CRPC). However, in recent years, several new therapy strategies, such as immunotherapy, hormonal manipulations, chemotherapy agents and some bone-targeted therapies, have demonstrated an improvement in terms of overall survival in controlled trials. In 2012, the Spanish Oncology Genitourinary Group (SOGUG) published its recommendations for the treatment of patients with CRPC. Due to the recent appearance of important new data and the complexity of decision-making in this field, SOGUG herein provides updated recommendations for the treatment of patients with metastatic prostate cancer.
authors.affiliation: Instituto Valenciano de Oncología (IVO), Valencia, Spain. Electronic address: macliment@fivo.org.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Climent
authors.affiliation: Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: León-Mateos
authors.affiliation: Hospital Universitario Son Espases, Palma de Mallorca, Spain.
authors.forename: Aránzazu
authors.initials: A
authors.lastname: González Del Alba
authors.affiliation: Hospital Universitario Virgen del Rocío, Sevilla, Spain.
authors.forename: Begoña
authors.initials: B
authors.lastname: Pérez-Valderrama
authors.affiliation: Hospital Universitario Reina Sofía, Córdoba, Spain.
authors.forename: M José
authors.initials: MJ
authors.lastname: Méndez-Vidal
authors.affiliation: Hospital Clínic, IDIBAPS, Barcelona, Spain.
authors.forename: Begoña
authors.initials: B
authors.lastname: Mellado
authors.affiliation: Hospital General Universitario Gregorio Marañón, Madrid, Spain.
authors.forename: José Ángel
authors.initials: JÁ
authors.lastname: Arranz
authors.affiliation: Consorcio Hospitalario Provincial de Castellón, Castellón, Spain.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Sánchez-Hernández
authors.affiliation: Hospital Universitario de Guadalajara, Guadalajara, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Cassinello
authors.affiliation: Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Olmos
authors.affiliation: Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Carles
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: Asymptomatic; Castration-resistant prostate carcinoma; Chemotherapy; Hormonal therapies; Recommendations; Symptomatic